A Phase 2 interventional study of Tovinontrine (CRD-750) and Placebo in Heart Failure, Heart Failure With Reduced Ejection Fraction and Cardiovascular Diseases, sponsored by Cardurion Pharmaceuticals, Inc.. Completed at 139 sites in 19 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-01.
Sponsored by Cardurion Pharmaceuticals, Inc. · Phase 2, Interventional, and Treatment
The purpose of this study is to evaluate the safety and effectiveness of tovinontrine compared to placebo to lower NT-proBNP in patients with chronic heart failure with reduced ejection fraction.
6,331 studies on the registry are indexed under Heart Failure; 1,396 are open to participants now.
This study's enrollment of 557 is above the median of 76 across 4,049 interventional studies indexed under Heart Failure.
Browse Heart Failure studies →Cardurion Pharmaceuticals, Inc. is the lead sponsor of 12 studies on the registry; 2 are open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 4 (50%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Has evidence in the medical history supporting a diagnosis of clinical HF syndrome, functional class II to III, with the duration of at least 6 months prior to the time of Screening. The HF syndrome is defined by documentation of 1 or more of the following:
Exclusion Criteria:
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Tovinontrine (CRD-750)
Drug: Tovinontrine (CRD-750)
Drug: Tovinontrine (CRD-750)
Drug: Placebo
Tablets administered orally
Tablets administered orally
Change in biomarkers from Baseline to Week 12 - NT-proBNP by treatment group
The percent change in plasma NT-proBNP from Baseline to Week 12.
Time frame: Baseline to Week 12
Change in biomarkers at Week 12 - NT-proBNP
The percent change in plasma NT-proBNP will be calculated from Baseline to Week 12. The correlation of plasma concentration with percent change in plasma NT-proBNP will be evaluated.
Time frame: Baseline to Week 12
Change in biomarkers at week 12 by treatment group - cGMP
The percent change in urine and plasma cGMP from Baseline to Week 12.
Time frame: Baseline to Week 12
Change in biomarkers at week 12 by treatment group - BNP
The percent change in BNP from Baseline to Week 12.
Time frame: Baseline to Week 12
Change in the biomarker ratio at Week 12 - NT-proBNP
The percent change in the urine and plasma cGMP to NT-proBNP ratio at week 12
Time frame: Baseline to Week 12
Change in the biomarker ratio at Week 12 - BNP
The percent change in the urine and plasma cGMP to BNP ratio from Baseline to Week 12
Time frame: Baseline to Week 12
The change from baseline in the Kansas City Cardiomyopathy Questionnaire-23-Clinical Summary Score
Scaled 0 to 100 where lower scores represent worse health status than higher scores
Time frame: Baseline to Week 12
The change from baseline in the Kansas City Cardiomyopathy Questionnaire 23- Overall Summary Score
Scaled 0 to 100 where lower scores represent worse health status than higher scores
Time frame: Baseline to Week 12
The change from baseline in the Kansas City Cardiomyopathy Questionnaire-23-CSS - Categorical
The proportion of patients with \>=5, 10 and 20-point improvement in the KCCQ-23-CSS.
Time frame: Week 12
New York Heart Association Classification
Class I to IV are possible with a higher classification representing worsening heart failure status.
Time frame: Week 12
Treatment Emergent Adverse Events (TEAEs)
The number of participants with TEAEs including drug related AEs, serious AEs (SAEs), and AEs leading to study drug discontinuation.
Time frame: Baseline to Week 12
Showing the first 100 of 139 sites across 19 countries. Choose a country and city above to see the rest.
This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tovinontrine
Cardurion Pharmaceuticals, Inc.